Stanford scientists have discovered that cross-linking antigens can overcome sub-type bias in response to multi-strain vaccines and induce patients to have a complete, broad immune response to all included antigens.
Stanford researchers have developed a nanoparticle adjuvant with spatiotemporal controlled release of TLR7 agonist for broad protection against influenza or SARS-CoV-2.
Stanford researchers in the Mark Davis Lab have developed a human cell culture system to grow 3D immune organoids within hydrogel structures using limited cellular input that can be adapted to large screening assays for flexible downstream immunological readouts.